March 10, 2000
Money Is Putting People at Risk in Biomedical Research
When the Food and Drug Administration halted research into human-gene therapy at the University of Pennsylvania in January, after the death of a research subject, Jesse Gelsinger, administrators at universities across the United States took notice. If a research program at an Ivy League institution, run by a scientist as prominent as James M. Wilson, was being accused of serious breaches of law and ethical standards, what problems lurked in the growing number of
This content is only for subscribers. You can gain access by purchasing a:
Print Subscription
Digital Subscription
Already have an account? Log In Now.
-
Research
-
Linguistics
-
Advice
